{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:49:01Z","timestamp":1788648541062,"version":"build-2803163510"},"reference-count":68,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>In the last decade, multikinase inhibitors (MKIs) have changed the paradigm of treatment of advanced and progressive thyroid cancer. Compared with the traditional treatment with chemotherapy and radiotherapy, these new drugs have shown a good efficacy in controlling the neoplastic disease, and also a different toxicity profile compared to traditional chemotherapy, milder but still present and involving mainly the nutritional profile. Weight loss, nausea, anorexia, stomatitis, diarrhea may be associated with malnutrition and cancer-related cachexia. The latter is characteristic of the advanced cancer stage and may be present before starting MKIs, or may develop afterwards. Adverse events with nutritional impact may cause a significant impairment of quality of life, often requiring dose reduction and sometimes drug discontinuation, but with a lower efficacy on the neoplastic disease. The aim of this paper was to discuss the role of nutritional therapy in advanced thyroid cancer and the importance of prevention, early recognition and careful management of malnutrition and cachexia during systemic therapy with MKIs.<\/jats:p>","DOI":"10.3390\/nu14061298","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:34:27Z","timestamp":1647812067000},"page":"1298","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nutrition in Advanced Thyroid Cancer Patients"],"prefix":"10.3390","volume":"14","author":[{"given":"Laura","family":"Agate","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Minaldi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-7080","authenticated-orcid":false,"given":"Alessio","family":"Basolo","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Angeli","sequence":"additional","affiliation":[{"name":"Dietary Service, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Jaccheri","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-0822","authenticated-orcid":false,"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9257","authenticated-orcid":false,"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute, and Bethesda, M. (2022). SEER Cancer Stat Facts: Thyroid Cancer, National Cancer Institute."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jc.2005-1322","article-title":"Survival and death causes in differentiated thyroid carcinoma","volume":"91","author":"Corssmit","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2017.12.027","article-title":"Predictive factors of outcome in poorly differentiated thyroid carcinomas","volume":"92","author":"Berthiller","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Prete, A., Matrone, A., Gambale, C., Torregrossa, L., Minaldi, E., Romei, C., Ciampi, R., Molinaro, E., and Elisei, R. (2021). Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. Cancers, 13.","DOI":"10.3390\/cancers13133200"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lorusso, L., Cappagli, V., Valerio, L., Giani, C., Viola, D., Puleo, L., Gambale, C., Minaldi, E., Campopiano, M.C., and Matrone, A. (2021). Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063117"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Matrone, A., Gambale, C., Prete, A., Piaggi, P., Cappagli, V., Bottici, V., Romei, C., Ciampi, R., Torregrossa, L., and De Napoli, L. (2020). Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13010094"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Basolo, A., Matrone, A., Elisei, R., and Santini, F. (2021). Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. Seminars in Cancer Biology, Academic Press.","DOI":"10.1016\/j.semcancer.2020.12.008"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/ERC-17-0016","article-title":"Timing of multikinase inhibitor initiation in differentiated thyroid cancer","volume":"24","author":"Brose","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/thy.2020.0276","article-title":"Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer","volume":"31","author":"Giani","year":"2021","journal-title":"Thyroid"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy with BLU-667 for RET-Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib Treatment in Patients with Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S1086","DOI":"10.1016\/j.annonc.2020.08.1404","article-title":"1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer","volume":"31","author":"Cabanillas","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","article-title":"GLIM criteria for the diagnosis of malnutrition\u2014A consensus report from the global clinical nutrition community","volume":"38","author":"Cederholm","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: Clinical Nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s11745-004-1346-8","article-title":"Effect of cancer cachexia on triacylglycerol\/fatty acid substrate cycling in white adipose tissue","volume":"39","author":"Beck","year":"2004","journal-title":"Lipids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12976-015-0015-0","article-title":"Modeling the energetic cost of cancer as a result of altered energy metabolism: Implications for cachexia","volume":"12","author":"Friesen","year":"2015","journal-title":"Theor. Biol. Med. Model."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","article-title":"Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d","volume":"29","author":"Muscaritoli","year":"2010","journal-title":"Clin. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1532-5415.2002.50216.x","article-title":"Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability","volume":"50","author":"Janssen","year":"2002","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","article-title":"Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?","volume":"34","author":"Andreyev","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jand.2016.05.010","article-title":"Oncology Evidence-Based Nutrition Practice Guideline for Adults","volume":"117","author":"Thompson","year":"2017","journal-title":"J. Acad. Nutr. Diet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000504048","article-title":"Body Composition and Leptin\/Ghrelin Levels during Lenvatinib for Thyroid Cancer","volume":"9","author":"Colombo","year":"2020","journal-title":"Eur. Thyroid. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12020-019-02162-x","article-title":"Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas","volume":"68","author":"Yamazaki","year":"2020","journal-title":"Endocrine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1210\/jc.2015-3989","article-title":"Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer","volume":"101","author":"Robinson","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Takada, H., Kurosaki, M., Nakanishi, H., Takahashi, Y., Itakura, J., Tsuchiya, K., Yasui, Y., Tamaki, N., Takaura, K., and Komiyama, Y. (2018). Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198812"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ravasco, P. (2019). Nutrition in Cancer Patients. J. Clin. Med., 8.","DOI":"10.3390\/jcm8081211"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","article-title":"Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bossi, P., Delrio, P., Mascheroni, A., and Zanetti, M. (2021). The Spectrum of Malnutrition\/Cachexia\/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients, 13.","DOI":"10.3390\/nu13061980"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clnu.2010.07.015","article-title":"Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients","volume":"30","author":"Hill","year":"2011","journal-title":"Clin. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1758835919880084","DOI":"10.1177\/1758835919880084","article-title":"From guidelines to clinical practice: A roadmap for oncologists for nutrition therapy for cancer patients","volume":"11","author":"Muscaritoli","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/sj.bmt.1704963","article-title":"Poor nutritional status prior to peripheral blood stem cell transplantation is associated with increased length of hospital stay","volume":"35","author":"Horsley","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Beaudart, C., McCloskey, E., Bruy\u00e8re, O., Cesari, M., Rolland, Y., Rizzoli, R., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Bautmans, I., and Berti\u00e8re, M.C. (2016). Sarcopenia in daily practice: Assessment and management. BMC Geriatr., 16.","DOI":"10.1186\/s12877-016-0349-4"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"key":"ref_51","unstructured":"Voss, A.C., and Williams, V. Oncology Nutrition for Clinical Practice, [2nd ed.]. Available online: https:\/\/www.eatrightstore.org\/product-type\/books\/oncology-nutrition-for-clinical-practice-2nd-edition."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0277-5379(91)90050-N","article-title":"Elevated energy expenditure in cancer patients with solid tumours","volume":"27","author":"Hyltander","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"ref_53","first-page":"1801","article-title":"Energy balance and body composition in cancer patients","volume":"38","author":"Warnold","year":"1978","journal-title":"Cancer Res."},{"key":"ref_54","first-page":"229","article-title":"Excessive caloric expenditure as a cause of malnutrition in patients with cancer","volume":"150","author":"Bozzetti","year":"1980","journal-title":"Surg. Gynecol. Obstet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3465s","DOI":"10.1093\/jn\/132.11.3465S","article-title":"Dietary intake, resting energy expenditure, weight loss and survival in cancer patients","volume":"132","author":"Bosaeus","year":"2002","journal-title":"J. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group","volume":"14","author":"Bauer","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12094-018-1978-1","article-title":"SEOM clinical guidelines on nutrition in cancer patients (2018)","volume":"21","author":"Majem","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.dld.2014.01.160","article-title":"Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment","volume":"46","author":"Senesse","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1017\/S0022215116000402","article-title":"Nutritional management in head and neck cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Talwar","year":"2016","journal-title":"J. Laryngol. Otol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/ans.13374","article-title":"Radiotherapy in well-differentiated thyroid cancer: Is it underutilized?","volume":"86","author":"So","year":"2016","journal-title":"ANZ J. Surg."},{"key":"ref_61","first-page":"E01","article-title":"Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer","volume":"88","author":"Chen","year":"2009","journal-title":"Ear Nose Throat J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00520-015-2958-4","article-title":"Nutrition intervention approaches to reduce malnutrition in oncology patients: A systematic review","volume":"24","author":"Lee","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur. Thyroid J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-5918-6-7","article-title":"Management of intestinal failure in Europe. A questionnaire based study on the incidence and management","volume":"6","author":"Staun","year":"2007","journal-title":"Dyn. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","article-title":"ESPEN guidelines on definitions and terminology of clinical nutrition","volume":"36","author":"Cederholm","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/bmj.a301","article-title":"Refeeding syndrome: What it is, and how to prevent and treat it","volume":"336","author":"Mehanna","year":"2008","journal-title":"BMJ"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1743-7075-8-54","article-title":"Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial","volume":"8","author":"Schmidt","year":"2011","journal-title":"Nutr. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3892\/ijo.2014.2382","article-title":"ERGO: A pilot study of ketogenic diet in recurrent glioblastoma","volume":"44","author":"Rieger","year":"2014","journal-title":"Int. J. Oncol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/6\/1298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:39:17Z","timestamp":1760135957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/6\/1298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["nu14061298"],"URL":"https:\/\/doi.org\/10.3390\/nu14061298","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}